



## Women's Sexual and Reproductive Health

### COVID-19 Coalition

# Using telehealth to provide early medical abortion during the COVID-19 pandemic and beyond: a consensus statement

*The Coalition makes the following recommendations:*

- 1. That MBS telehealth item numbers continue to be available to all Australian women (including both rural and urban women) for the purpose of accessing EMA via telehealth through Medicare.*
- 2. That South Australian state government legislation is changed to remove the restriction of supply of mifepristone to solely hospital grounds to allow for provision of EMA in primary care and via telehealth.*

Telehealth is the use of telecommunication technology to provide healthcare and can be used to provide a range of healthcare services (1), including early medical abortion (EMA) (1, 2). Telehealth EMA is considered comparable in safety, efficacy, and acceptability to in-person EMA and can significantly improve accessibility of EMA for women\* (1, 3). Non-directive pregnancy counselling, assessing eligibility for EMA, gaining informed consent, supplying medications (mifepristone and misoprostol), and assessing completion of EMA can all be successfully delivered by telehealth (1,4).

National and international peak bodies have recommended the use of telehealth services to increase timely access to EMA for women during COVID-19 (5-8).

Commencing on 13 March 2020, new temporary MBS telehealth items were made available to help reduce the risk of community transmission of COVID-19 and provide protection for patients and health care providers. These item numbers are available to a number of health professionals, including specialist doctors, General Practitioners (GPs), allied health workers, nurse practitioners, practice nurses, midwives, and mental health nurses (9). The availability of these MBS items has made telehealth EMA accessible to Australian women for the first time through Medicare. However, these MBS telehealth items are scheduled for review in September. Alterations to the eligibility of these MBS items (for example, restricting eligibility to elderly patients or those with a chronic disease or to patients who have consulted that doctor in the previous 12 months) will exclude the very women who require telehealth EMA services from being able to access them particularly vulnerable women, including those living in regional or remote communities (10).

\*The coalition uses *women* as an inclusive and broad term that refers to and acknowledges the diversity in needs and experiences of all people who may require access to hormonal contraception, abortion and women's sexual and reproductive health services



We also note that under current legislation in South Australia, mifepristone can only be supplied in a hospital setting (11). EMA is therefore unable to be delivered by telehealth to South Australian women, placing them at increased risk during the pandemic and beyond.

## REFERENCES

1. Endler M, Lavelanet A, Cleeve A, Ganatra B, Gomperts R, Gemzell-Danielsson K. Telemedicine for medical abortion: a systematic review. *BJOG : an international journal of obstetrics and gynaecology*. 2019.
2. DeNicola N, Grossman D, Marko K, Sonalkar S, Butler Tobah YS, Ganju N, et al. Telehealth Interventions to Improve Obstetric and Gynecologic Health Outcomes: A Systematic Review. *Obstetrics and gynecology*. 2020;135(2):371-82.
3. Grindlay K, Lane K, Grossman D. Women's and providers' experiences with medical abortion provided through telemedicine: a qualitative study. *Women's health issues : official publication of the Jacobs Institute of Women's Health*. 2013;23(2):e117-22.
4. World Health Organization. Telemedicine: opportunities and developments in Member States: report on the second global survey on eHealth 2009. Report. Geneva, Switzerland: World Health Organization; 2010.
5. Bayefsky MJ, Bartz D, Watson KL. Abortion during the Covid-19 Pandemic - Ensuring Access to an Essential Health Service. *The New England journal of medicine*. 2020.
6. Royal College of Obstetricians and Gynaecologists (RCOG). Coronavirus (COVID-19) infection and abortion care. Information for healthcare professionals. UK: Royal College of Obstetricians and Gynaecologists; 2020 1 April 2020.
7. Costescu D, Guilbert E, Wagner M-S, Dunn S, Norman WV, Black A, et al. Induced Abortion: Updated Guidance during pandemics and periods of social disruption Canada: Society of Obstetricians and Gynaecologists Canada (SOGC); 2020 [updated unknown date unknown month 2020 Available from: <https://sogc.org/en/-COVID-19/en/content/COVID-19/COVID-19.aspx?hkey=4e808c0d-555f-4714-8a4a-348b547dc268>.
8. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). COVID-19: Access to reproductive health services Australia: The Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2020 [updated 08 April 2020. Available from: <https://ranzcog.edu.au/news/covid-19-access-to-reproductive-health-services>.
9. Australian Government Department of Health. COVID-19 Temporary MBS Telehealth Services Australia: Australian Government of Health; 2020 [updated 20 April 2020; cited 2020 23/04/2020]. Available from: <http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Factsheet-TempBB>.
10. Doran F, Nancarrow S. Barriers and facilitators of access to first-trimester abortion services for women in the developed world: a systematic review. *J Fam Plan Reprod Health Care*. 2015;41(3):170-80.
11. Children by Choice Incorporated. Australian abortion law and practice [Web page]. Internet 2019 [cited 2019 05/03/2019]. Available from: <https://www.childrenbychoice.org.au/factsandfigures/australianabortionlawandpractice>.